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L-Citrulline is an effective precursor of L-arginine produced by the L-citrulline/L-arginine cycle, and it
exerts beneﬁcial effects on the cardiovascular system by supporting enhanced nitric oxide (NO) pro-
duction. NO dilates retinal blood vessels via the cyclooxygenase-mediated pathway. The purpose of this
study was to examine the effects of L-citrulline on retinal circulation and to investigate the potential
involvement of NO and prostaglandins in L-citrulline-induced responses in rats. L-Citrulline (10
e300 mg kg1 min1, i.v.) increased the diameter of retinal arterioles without signiﬁcantly changing mean
blood pressure, heart rate, and fundus blood ﬂow. The vasodilator response of retinal arterioles to L-
citrulline was signiﬁcantly diminished following treatment with NG-nitro-L-arginine methyl ester
(30 mg/kg, i.v.), an NO synthase inhibitor, or indomethacin (5 mg/kg, i.v.), a cyclooxygenase inhibitor. In
addition, a-methyl-DL-aspartic acid (147 mg/kg, i.v.), an inhibitor of argininosuccinate synthase, the rate-
limiting enzyme for the recycling of L-citrulline to L-arginine, diminished the L-citrulline-induced retinal
vasodilation. These results suggest that both NO- and prostaglandin-dependent pathways contribute to
the L-citrulline-induced vasodilation of rat retinal arterioles. The L-citrulline/L-arginine recycling pathway
may have more importance in regulating vascular tone in retinal blood vessels than in peripheral
resistance vessels.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The vascular endothelium plays a crucial role in regulating
retinal blood ﬂow, and it performs this role via several vasodilators,
including nitric oxide (NO), prostanoids (e.g., prostaglandin I2), and
endothelium-derived hyperpolarizing factor (EDHF) (1e4). In the
vascular endothelium, NO is produced by endothelial NO synthase
(eNOS), which uses L-arginine as a substrate and produces L-
citrulline as a by-product. The L-citrulline to L-arginine recycling
pathway consists of two enzymes, argininosuccinate synthase and
argininosuccinate lyase, which are present in endothelial cells and
other cell types (5,6). In endothelial cells, plasmalemmal cav-
eolaedthe site of the L-citrulline/L-arginine recycling path-
waydmay be the principal source of L-arginine (7,8).Mori).
rmacological Society.
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d/4.0/).L-Citrulline is an a-amino acid isolated from watermelon juice,
and it is beneﬁcial to the cardiovascular system (9). In isolated
blood vessel preparations, L-citrulline induced endothelium-
dependent relaxation by enhancing the release of NO; this NO
release could be due to the recycling of L-citrulline to L-arginine
(10). Furthermore, L-citrulline supplementation exhibits several
beneﬁcial effects on the cardiovascular system (11e14). However,
the effect of L-citrulline on retinal blood vessels and the importance
of the L-citrulline/L-arginine recycling pathway for the regulation of
retinal circulation remain to be elucidated.
Retinal blood vessels anatomically and functionally resemble
cerebral blood vessels (3,16), and they have different characteristics
compared to blood vessels in other peripheral circulatory beds. In
most vascular beds, NO dilates blood vessels by activating soluble
guanylyl cyclase and elevating intracellular cGMP levels. However,
in rat retinal vasculature, NO preferentially stimulates the
cyclooxygenase-1/cAMP-mediated pathway (17). Furthermore, in
diabetic conditions, retinal and systemic vascular endothelial cellsnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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endothelium-dependent vasodilatory mechanisms of retinal arte-
rioles are more vulnerable than those of peripheral resistance
vessels to the effects of hyperglycemia (18,19). Thus, the importance
of the L-citrulline/L-arginine recycling pathway in regulating
vascular tone may differ between retinal and peripheral
vasculature.
To test this hypothesis, we examined 1) the effects of intrave-
nously administered L-citrulline on the diameter of retinal blood
vessels and blood pressure, and 2) how NG-nitro-L-arginine methyl
ester (L-NAME), a non-selective inhibitor of NOS, indomethacin, a
non-selective inhibitor of cyclooxygenase, and a-methyl-DL-
aspartic acid (a-MDLA), a selective inhibitor of argininosuccinate
synthetase, affect the responses to L-citrulline in rats.
2. Materials and methods
2.1. Animals
Twenty six male Wistar rats (8- to 10-week-old) were main-
tained in a room with constant temperature (22 ± 2 C), constant
humidity (55 ± 5%) and a 12-h light/dark cycle, and they were
allowed free access to standard rat chow and tap water. All animal
procedures were performed in accordance with the Association for
Research in Vision and Ophthalmology Statement on the Use of
Animals in Ophthalmic and Vision Research and the Regulations for
the Care and Use of Laboratory Animals adopted by the Institutional
Animal Care and Use Committee at Kitasato University.
2.2. Experimental procedures
The experimental procedures used in this study were described
previously (20,21). Brieﬂy, rats were anesthetized with pentobar-
bital sodium (50 mg/kg, i.p.). After disappearance of the corneal
reﬂex, each animal was placed on a heating pad. A tracheotomywas
performed for artiﬁcial ventilation. Catheters were inserted into the
femoral and jugular veins for drug administration. The left femoral
artery was cannulated to measure arterial pressure, which was
recorded on a thermal pen recorder (WT-645G, Nihon Kohden,
Tokyo, Japan) via a pressure transducer (DX-360, Nihon Kohden)
and a preampliﬁer (AP-610G, Nihon Kohden). Heart rate was
measured using a cardiotachometer (AT-601G, Nihon Kohden)
triggered by the blood pressure pulse. Mean arterial pressure and
heart rate were digitized at 1 Hz (15BXW-H4; Dacs Giken,
Okayama, Japan) and stored on the hard disk of a personal com-
puter. To minimize the inﬂuence of nerve activity and capture
fundus images at the same angle throughout the experiment, rats
were treated with tetrodotoxin (50 mg/kg, i.v.) to prevent eye
movement under artiﬁcial ventilation with room air (the stroke
volume, 10 mL/kg; the frequency, 80 strokes/min) using a rodent
respirator (SN-480-7, Shinano, Tokyo, Japan). Blood pressure and
heart rate were decreased after treatment with tetrodotoxin;
therefore, methoxamine was continuously injected into the jugular
vein at a constant rate using a syringe pump (Model 1140-001,
Harvard Apparatus, South Natick, MA, USA) to maintain adequate
systemic circulation. Treatment with L-NAME, indomethacin, or a-
MDLA was performed just before starting the methoxamine infu-
sion. The dose of methoxamine was ~40 mg kg1 min1
(~5 mg kg1 min1 for L-NAME-treated rats).
In the ﬁrst series of experiments, we examined the effects of
intravenous infusion of L-citrulline (10e300 mg kg1 min1, i.v.) on
the diameter of retinal arterioles, blood pressure and heart rate
(n¼ 5). L-Citrulline solutionwas infused into the femoral vein using
a syringe pump (Harvard Apparatus), and the infusion rate was
sequentially increased in a stepwise fashion. For comparison, salinewas infused with the same procedure (n ¼ 3). To examine the
possible involvement of NO and prostaglandins in L-citrulline-
induced responses, L-citrulline infusion was performed as
mentioned above in rats treated with L-NAME (30 mg/kg, i.v., n¼ 5)
or indomethacin (5 mg/kg, i.v., n ¼ 5). The doses of L-NAME and
indomethacin were chosen based on previous reports from our lab
(17,18,22).
In the second series of experiments, we examined L-citrulline-
induced responses after treatment with a-MDLA (147mg/kg, n¼ 4)
or its vehicle (n ¼ 4) to determine the role of L-citrulline/L-arginine
recycling pathway in the L-citrulline-induced vasodilation of retinal
arterioles. a-MDLA was reported to selectively inhibit arginino-
succinate synthetase (23). The dose of a-MDLA was chosen based
on a previous study showing its effectiveness in vivo (23).
2.3. Fundus photography and retinal arteriolar diameter
measurement
The techniques used for fundus photography and retinal arte-
riolar diameter measurement were previously described
(18,19,21,22,24,25). Brieﬂy, hydroxyethylcellulose (SCOPISOL 15®,
Senju Pharmaceutical, Osaka, Japan) was dropped onto the cornea
of rats to prevent drying of the eye. The optic disc was centered and
focused in the ﬁeld of view. Sodium ﬂuorescein (10% solution,
0.8 mL/kg) and brilliant blue 6B (5% solution, 0.8 mL/kg) were
injected into the right femoral vein to enhance blood vessel
contrast. Fundus images were captured using a digital camera
(Finepix S3 pro; Fuji Photo Film, Tokyo, Japan) equippedwith a bore
scope-type objective lens for small animals (Model 01; Scalar,
Tokyo, Japan), and theywere stored on the hard disk of a laboratory
computer system. A region (120  240 mm) including a retinal
arteriole in the fundus image (2820  4230 mm) was selected for
analysis, and the diameter of blood vessel in the same region was
measured throughout the experiment.
2.4. Measurement of fundus blood ﬂow
Fundus blood ﬂowwasmeasured as reported previously (21,26).
Brieﬂy, a non-contact probe for blood ﬂow measurement (outer
diameter, 0.5 mm) was placed along the bore scope-type objective
lens at an angle of approximately 30. Blood ﬂow in the region
including the optic nerve head (fundus blood ﬂow) was assessed
using laser Doppler blood-ﬂowmetry (Omega Flow FLO-N1, Ome-
gawave, Tokyo, Japan). The fundus was monitored using the fundus
camera prior to the start of the experiment to conﬁrm the region of
fundus to be illuminated by the laser. Fundus blood ﬂow was
digitized at 1 Hz using 15BXW-H4 (Dacs Giken) and recorded on an
ink-writing recorder (R-62, Rikadenki Kogyo, Tokyo, Japan). The
digitized blood ﬂow data and fundus images were stored on the
hard disk of a laboratory computer system.
2.5. Drugs
L-Citrulline was produced from KYOWA HAKKO BIO CO., LTD
(Ibaraki, Japan). Indomethacin, L-NAME, methoxamine and a-MDLA
were obtained from SigmaeAldrich (St. Louis, MO, USA), and
tetrodotoxin was obtained from Nacalai Tesque (Kyoto, Japan).
Indomethacin was dissolved in 0.24% Na2CO3, and all other drugs
were dissolved in saline.
2.6. Data analyses
The diameter of the retinal arteriole, mean arterial pressure, and
heart rate were expressed as percentages of the baseline values
(mean values of data obtained at the time from 2 min to 0 min)
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groups and more than 2 groups, we used unpaired t-test and
Tukey's test, respectively. When comparing the responses between
groups, two-way analysis of variance (Two-way ANOVA) was used.
A P value less than 0.05 was considered statistically signiﬁcant. All
values are presented as the mean ± S.E.M.
3. Results
The baseline values of retinal arteriolar diameter, mean arterial
pressure and heart rate of the rats used in this study are summa-
rized in Table 1. Compared to controls, the baseline retinal arteriolar
diameter was smaller in L-NAME-treated rats and baseline mean
arterial pressure was higher. Other parameters were not signiﬁ-
cantly different among the experimental groups.
Fig. 1 shows representative fundus images captured at baseline
and 10 min after starting L-citrulline (300 mg/kg, i.v.) infusion; L-
citrulline clearly increased the diameter of retinal arterioles. In this
case, the diameter of the arteriole in the selected region increased
by 24.8%. A summary of the data is shown in Fig. 2. Saline did not
elicit signiﬁcant responses, whereas L-citrulline
(10e300 mg kg1 min1, i.v.) increased the diameter of retinal ar-
terioles in a dose-dependent manner (Fig. 2A). L-Citrulline-induced
vasodilator responses were almost completely prevented by L-
NAME (30mg/kg, i.v.) (Fig. 2A). In addition, indomethacin (5 mg/kg,
i.v.) signiﬁcantly attenuated the L-citrulline-induced retinal
vascular response. In contrast, L-citrulline had no signiﬁcant effect
on mean arterial pressure (Fig. 2B) or heart rate (Fig. 2C). L-Citrul-
line (10e300 mg kg1 min1, i.v.) did not increase fundus blood ﬂow
(e.g., Saline, 3.2 ± 1.2%, n ¼ 3 vs. 300 mg kg1 min1 of L-citrulline,
4.5 ± 0.8%, n ¼ 5).
Increases in retinal arteriolar diameter induced by L-citrulline
were signiﬁcantly attenuated by a-MDLA (147 mg/kg, i.v.) (Fig. 3A).
a-MDLA showed the tendency to enhance the L-citrulline-induced
depressor response, but the difference was not statistically signif-
icant (Fig. 3B). However, the inhibitor had no effect on heart rate
(Fig. 3C).
4. Discussion
The present study demonstrates that intravenously adminis-
tered L-citrulline dilates retinal arterioles without signiﬁcantly
effecting systemic blood pressure, heart rate and fundus blood
ﬂow in rats. The vasodilator responses of retinal arterioles to L-
citrulline were signiﬁcantly attenuated by L-NAME and indo-
methacin treatment. These results suggest that L-citrulline dilates
retinal arterioles to a greater extent than peripheral resistance
vessels, and both NO- and prostaglandin-dependent pathwaysTable 1
Values of mean arterial pressure (MAP), heart rate (HR) and retinal arteriolar
diameter (AD) in each experimental group.
Experimental groups MAP (mmHg) HR (beats/min) AD (mm)
Experiment 1
Control (n ¼ 5) 113 ± 2 361 ± 13 39.4 ± 1.1
L-NAME (n ¼ 5) 144 ± 5* 384 ± 17 31.5 ± 1.3*
Indomethacin (n ¼ 5) 114 ± 3 375 ± 14 35.6 ± 2.0
Saline infusion (n ¼ 3) 104 ± 2 396 ± 13 41.9 ± 2.3
Experiment 2
Control (n ¼ 4) 109 ± 2 423 ± 6 38.3 ± 2.6
a-MLDA (n¼ 4) 111 ± 2 456 ± 17 36.8 ± 1.0
Values represent the mean ± S.E.M. These values were measured just before starting
L-citrulline or saline infusion.
* P<0.05 vs. the corresponding values of the Saline infusion group. L-NAME; NG-
nitro-L-arginine methyl ester, a-MLDA; a-methyl-DL-aspartic acid.contribute to the L-citrulline-induced vasodilation of retinal arte-
rioles in rats. Thus, we have shown for the ﬁrst time that systemic
administration of L-citrulline exerts vasodilator actions on the
retinal vascular system.
In the retinal vasculature, as well as other many vasculatures,
NO is an important regulator of vascular tone. However, down-
stream signals elicited by NO are different between retinal and
peripheral blood vessels, because indomethacin signiﬁcantly pre-
vented the vasodilation of retinal arterioles, but not depressor
response, to NO donors in rats (17). In the present study, L-NAME
almost completely prevented the L-citrulline-induced vasodilator
response in retinal arterioles, while indomethacin diminished L-
citrulline-induced responses by approximately 60%. Therefore, L-
citrulline appears to cause the retinal vasodilator response via
enhancing the NO signaling pathway. The NO-mediated compo-
nent of the L-citrulline-induced response is likely mediated by
stimulation of the cyclooxygenase-mediated pathway. Further
studies are needed to determine which prostanoids (i.e., PGI2 and
PGE2) play an important role in the L-citrulline-mediated retinal
vasodilator response. However, we previously reported that intra-
venous administration of these vasodilatory prostanoids increased
the diameter of retinal blood vessels in rats (21). More recently, we
found that the PGI2 receptor (IP) antagonist CAY-10441 signiﬁcantly
attenuated retinal vasodilator responses to NO donors (unpub-
lished data). Therefore, PGI2 may contribute to play an important
role in L-citrulline-mediated retinal vasodilator response in rats.
Interestingly, our previous studies demonstrated that both PGI2
and PGE2 increased fundus blood ﬂow and retinal blood vessel
diameter (21). In contrast, in the present study, L-citrulline dilated
retinal arterioles primarily through the cyclooxygenase-mediated
pathway, and it did not increase fundus blood ﬂow. The laser-
Doppler ﬂow meter system used in this and previous studies can
penetrate tissue to a depth of approximately 1 mm (26). Therefore,
both retinal and choroidal blood ﬂow could be measured as a
fundus blood ﬂow. However, blood ﬂow of retinal circulation is
much less than that of choroidal circulation (27). Under our
experimental conditions, approximately 70% of fundus blood ﬂow
was derived from choroidal blood ﬂow. Thus, changes in choroidal
blood ﬂow might signiﬁcantly inﬂuence the fundus blood ﬂow
determined by our system. These results suggest that, L-citrulline,
unlike PGI2 and PGE2, dilates retinal arterioles to a greater extent
than it does choroidal blood vessels, and it does not substantial
affect choroidal vasculature.
L-Arginine is converted to NO and L-citrulline by eNOS in the
vascular endothelium. L-Citrulline can be recycled to L-arginine in a
two-step reaction involving argininosuccinate synthase and argi-
ninosuccinate lyase (5e8). Therefore, we examined effects of a-
MDLA, a selective inhibitor of arginosuccinate synthase, on L-
citrulline-induced vasodilation of retinal arterioles and found that
a-MDLA signiﬁcantly attenuated the L-citrulline-induced response.
Thus, the L-citrulline/L-arginine recycling pathway seems to be
involved in the L-citrulline-induced retinal vasodilator response.
L-Citrulline increases plasma L-arginine concentration more
efﬁciently than L-arginine (15) and oral L-citrulline supplementa-
tion exhibits several beneﬁcial effects on the cardiovascular system
(11e15). For example, a more recent study demonstrated that
supplemental L-citrulline prevents hypertension in young sponta-
neously hypertensive rats, whereas L-citrulline therapy had no
signiﬁcant effect on blood pressure in normotensive Wistar-Kyoto
rats (28). Consistent with the results, we found that intravenously
administered L-citrulline did not affect systemic blood pressure in
normotensive rats. The mechanism underlying the difference in L-
citrulline potency between retinal and peripheral circulation is
unclear; however, these results indicate that the L-citrulline/L-
arginine recycling pathway may be more important for regulating
Fig. 1. Representative fundus images before (A) and 10 min (B) after starting infusion of L-citrulline (300 mg kg1 min1, i.v.) in rats. The diameter of the retinal arteriole in the
selected region is expressed as a percentage of the baseline value before L-citrulline infusion. The diameter of the retinal arteriole increased by 24.8%.
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vessels.
Impairment of retinal circulation contributes to the pathogen-
esis of several ocular diseases. For example, the long-term hyper-
glycemia causes narrowing of retinal blood vessels and reduction in
retinal blood ﬂow that are associated with the onset of diabetic
retinopathy (29,30). Disturbances in retinal blood ﬂow and
oxygenation may be involved in the pathogenesis of glaucoma
(31,32). Therefore, agents that dilate retinal blood vessels represent
candidate therapeutics for preventing the development of ocular
diseases associated with impaired retinal circulation. Intravenously
administered L-citrulline could produce a vasodilator response in
retinal blood vessels without signiﬁcant hypotension and tachy-
cardia. These characteristics may be favorable as a novel thera-
peutic candidate to improve impaired retinal circulation. However,
it remains to be elucidated whether the vasodilator effects of L-Fig. 2. Effects of NG-nitro-L-arginine methyl ester (L-NAME, 30 mg/kg, i.v.) and indo-
methacin (Indo, 5 mg/kg, i.v.) on changes in retinal arteriolar diameter (A), mean
arterial pressure (B), and heart rate (C) induced by L-citrulline. For comparison, saline
was infused with the same procedure (Saline infusion). Data are expressed as per-
centages of the baseline values measured just prior to L-citrulline or saline infusion.
Each point with a vertical bar represents the mean ± S.E.M. of 3e5 animals. #P < 0.05.citrulline on retinal blood vessels are affected in pathological con-
ditions. Furthermore, our previous studies demonstrated that
acetylcholine-induced vasodilation of retinal arterioles was
diminished in diabetic rats (18,19). Using the same diabetic model,
it would be interesting to determine whether L-citrulline supple-
mentation prevents the impairment of acetylcholine-induced
responses.
5. Conclusions
We have shown for the ﬁrst time that intravenously adminis-
tered L-citrulline dilates rat retinal blood vessels without signiﬁ-
cantly effecting systemic blood pressure and heart rate in vivo. The
vasodilator responses of retinal arterioles to L-citrulline seem to be
mediated by NO- and prostaglandin-dependent pathways. The
present study also provides the ﬁrst evidence that the L-citrulline/L-Fig. 3. Effects of a-methyl-DL-aspartic acid (a-MDLA, 147 mg/kg, i.v.) on changes in
retinal arteriolar diameter (A), mean arterial pressure (B), and heart rate (C) induced by
L-citrulline. Data are expressed as percentages of the baseline values measured just
prior to L-citrulline infusion. Each point with a vertical bar represents the
mean ± S.E.M. of 4 animals. #P < 0.05.
A. Mori et al. / Journal of Pharmacological Sciences 127 (2015) 419e423 423arginine recycling pathway may play an important role in regu-
lating vascular tone in retinal blood vessels.
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